Search bioRxiv⌕ Search

Biology subjects

Schauer, M. P.

Publications and source records attributed to Schauer, M. P..

2 recordsLinked to original sources

Autocrine glucocorticoid signaling in hormonally active cancer induces antigen expression for immunotherapy

Exogenous glucocorticoids (GCs) suppress T cell-based immunotherapy, yet the consequences of endogenous GCs produced or regenerated by tumours remain poorly understood. Here, we show that tumour-derived GCs couple immune evasion to therapeutic antigenicity. In adrenocortical carcinoma, autonomous GC production activates hGR-STAT3 signaling to increase the surface antigen ROR1. This creates an immunological paradox in which GC excess promotes therapeutic antigen expression while suppressing T cell-mediated antitumor activity. Selective hGR-knockout renders ROR1 CAR-T cells GC-resistant while preserving GC-driven ROR1 expression in tumor cells, resulting in durable tumor control in vivo. Non-endocrine pancreatic and triple-negative breast cancers recreate this circuit through HSD11B1-mediated GC recycling, which is further induced by CAR-T cell-derived cytokines under immune pressure. Thus, GC-resistant CAR-T cells exploit a tumor-derived endocrine program that couples immune suppression to therapeutic antigenicity.

cancer biology↗

Cellular landscape of adrenocortical carcinoma at single-nuclei resolution

Adrenocortical carcinoma (ACC) is a rare yet devastating tumour of the adrenal gland with a molecular pathology that remain incompletely understood. To gain novel insights into the cellular landscape of ACC, we generated single-nuclei RNA sequencing (snRNA-seq) data sets from twelve ACC tumour samples and analysed these alongside a previously published snRNA-seq data set from normal adrenal glands (NAGs). We find the ACC tumour microenvironment to be relatively devoid of immune cells compared to NAG tissues, consistent with known high tumour purity values for ACC as an immunologically "cold" tumour. Our analysis identifies three separate groups of ACC samples that are characterised by different relative compositions of adrenocortical cell types, including two populations (ACC 1 and ACC 2) that are specifically enriched in the most aggressive tumours and display hallmarks of the epithelial to mesenchymal transition (EMT) and dysregulated steroidogenesis, respectively. In addition to cell types associated with hypoxic and metabolic signatures (ACC 3 and ACC 4) prevalent among less-aggressive tumours, we also identified and validated a population of mitotically active adrenocortical cells (ACC M) strongly overexpressing genes POLQ and DIAPH3 that possibly supports the expansion of malignant cell lineages. The smallest identified ACC specific cell type, ACC 5, displays characteristics of increased proliferation and growth factor signalling, and is therefore a potential progenitor-like or cell-of-origin candidate for the different lineages involved in adrenocortical carcinogenesis. Intriguingly, linage tracing suggests the fate adopted by malignant adrenocortical cells upon differentiation appears to be at least partly associated with the copy number or allelic balance state of the imprinted DLK1/MEG3 genomic locus, which we verified by assessing DNA methylation status among samples from the three groups of tumours defined by their different cell type compositions. Our results therefore provide new insights into the cellular heterogeneity of ACC, indicating that genetic perturbations to a hierarchical cellular differentiation mechanism underlying healthy adrenocortical renewal and zonation may explain the molecular basis for disease pathogenesis.

cancer biology↗